Detalhe da pesquisa
1.
PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk.
Int J Mol Sci
; 24(3)2023 Jan 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36768645